FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series A / Biotech startups that raised Series A in China

Biotech startups that raised Series A in China

Updated 16 Nov 2026

Reset
Biotech startups that raised Series A in China
One-time CSV
  • 485 funded companies, 307 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-a~china-500a.csv485 rows × 18 columns
CompanyCityLast roundAmountDate
Phil Rivers TechnologyBeijingSeries A$29.6M2026-08-05
Tianhu TechnologyMinhangSeries A$29.0M2026-07-13
SynMetaBioShanghaiSeries A$14.7M2026-07-06
Prime LifescienceHangzhouSeries A$14.7M2026-06-30
Lingtai Krypton BiotechnologyShuangliuSeries A$13.7M2026-06-26
Artivila TherapeuticsShenzhenSeries A$14.7M2026-06-23
MoleculeMindHaidianSeries A$86.0M2026-06-17
Degron TherapeuticsShanghaiSeries A$40.0M2026-05-14

8 rows of the CSV in 5 of its 18 columns.

485
Startups
$6.9B
Total raised
103
Funded in the last 12 months
$1.5B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 485
30 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Phil Rivers Technology Phil Rivers Technology provides AI solutions for pharmaceutical research and development. Artificial intelligence Beijing Series A $29.6M 2026-08-05 $57.3M Insight Capital 51 to 100 2015
Tianhu Technology Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. Artificial intelligence Minhang Series A $29.0M 2026-07-13 $54.2M Qiming Venture Partners, GSR United Capital, 3E Bioventures 11 to 50 2021
SynMetaBio SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. Biotech Shanghai Series A $14.7M 2026-07-06 $16.1M MiraclePlus, Linear Capital, Danen Capital 11 to 50 2021
Prime Lifescience Prime Lifescience develops a big data platform for life sciences research and analysis. Biotech Hangzhou Series A $14.7M 2026-06-30 $44.5M Qiming Venture Partners, Qiji Investment, Ennovation Ventures 11 to 50 2021
Lingtai Krypton Biotechnology Lingtai Krypton Biotechnology develops lncRNA drugs to treat human diseases. Biotech Shuangliu Series A $13.7M 2026-06-26 $13.7M Legend Capital, Guosheng Capital, Firefly Haoyue 11 to 50 2021
Artivila Therapeutics Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. Artificial intelligence Shenzhen Series A $14.7M 2026-06-23 $53.3M Highlight Capital, Med-Fine Capital, Hike Capital +2 11 to 50 2018
MoleculeMind MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. Artificial intelligence Haidian Series A $86.0M 2026-06-17 $114.6M Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital 51 to 100 2022
Degron Therapeutics Degron Therapeutics discovers molecular glue degraders for cancer treatment. Biotech Shanghai Series A $40.0M 2026-05-14 $94.0M Baidu Ventures, BioVenture, New Alliance Capital +2 101 to 250 2021
Shanmu SHANMU Shanmu develops micro medical robots using digital microfluidic chipsets and artificial intelligence algorithms. Artificial intelligence Shenzhen Series A $14.7M 2026-05-06 $16.0M QF Capital, Hofan Venture, Wanwu Capital +1 1 to 10 2020
Neurodome Neurodome manufactures non-invasive deep brain nerve modulation technology and products. Biotech Xian Shi Series A $14.5M 2026-03-12 $14.5M Shunwei Capital, Frees Fund, Oriza Holdings +2 11 to 50 2019
iCamumo iCamumo develops off-the-shelf, general-purpose cell therapies using iPSCs. Biotech Suzhou Series A $14.4M 2026-03-09 $75.2M Delian Capital, West Lake Science and Technology Direct Investment Fund, Zhiyi Investment 51 to 100 2021
UniXell Biotechnology UniXell Biotechnology develops cell therapy drugs. Biotech Pudong Series A $7.2M 2026-02-11 $52.5M Hillhouse Investment, CDH Investments, Sherpa Healthcare Partners +1 11 to 50 2021
Xingsai Bio Xingsai Bio develops single-cell analysis instruments and related reagents and consumables. Biotech Qingdao Shi Series A $14.4M 2026-01-19 $28.3M Hengxu Capital, Haitang Fund, Neovision Capital +1 51 to 100 2014
Dishi Medical Dishi Medical manufactures ophthalmic medical devices and micro-assisted robots supported by biotechnology. Biotech Hangzhou Series A $13.7M 2026-01-19 $13.7M Hillhouse Investment, Fortune Venture Capital, Linear Capital +1 11 to 50 2021
Huixin Medical Valley Huixin Medical Valley develops cell therapies for neurological illnesses as a biopharmaceutical company. Biotech Changping Series A $14.3M 2026-01-07 $14.3M Green Pine Capital Partners, Jiuzhi Ziben, Beijing Venture Capital 51 to 100 2021
PRCXI Biotechnology PRCXI Biotechnology provides analytical instruments, bioinformatics, and automation solutions for life sciences. Biotech Suzhou Series A $14.0M 2025-12-31 $55.0M Qiming Venture Partners, SAIF Partners 101 to 250 2014
Allink Biotherapeutics Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. Biotech Shanghai Series A $47.0M 2025-12-16 $89.0M Legend Capital, Gaorong Capital, BioVenture +2 11 to 50 2023
Ningkang Ruizhu Ningkang Ruizhu develops targeted drugs. Biotech Zhuhai Series A $14.1M 2025-12-05 $25.6M GF Qianhe Investment, RiverHead Capital, Hanne Capital +1 11 to 50 2019
Kunshi Biotechnology Kunshi Biotechnology develops drugs with an emphasis on solid tumor cells. Biotech Suzhou Series A $7.0M 2025-11-20 $7.0M Deshi Capital 51 to 100 2021
Brise Pharma Brise Pharma provides scientific research and technical services in the pharmaceutical field. Biotech Shanghai Series A $28.1M 2025-11-11 $228.3M Qiming Venture Partners, Sherpa Healthcare Partners, BioTrack Capital +1 11 to 50 2021
Wimi bio Wimi Bio researches and develops gene editing and biological breeding technologies as a high-tech enterprise. Biotech Nanjing Series A $14.1M 2024-09-19 HosenCare Brothers 51 to 100 2017
Shandong Bona Group Shandong Bona Group develops material separation, extraction, and purification technologies as a biotechnology company. Biotech Jinan Series A $13.8M 2024-07-24 $13.8M Lucion, Jinan Jigao Finance 51 to 100 2012
AnDiConBio AnDiConBio develops respiratory anti-infection drugs for pain and respiratory conditions. Biotech Jiaxing Series A $27.6M 2024-04-29 $27.6M Cowin Capital, Wenzhou Capital, Huajin Avenue Investment 11 to 50 2018
Scitech pharma Scitech pharma uses AI to design and develop drugs focused on patient demand and clinical value. Biotech Shunyi Series A $13.8M 2024-04-26 Lichen Capital, Zhizhong Investment 251 to 500 2015
Aoshi Environmental Aoshi Environmental produces high-performance reverse osmosis and nanofiltration membrane separation products. Biotech Huzhou Series A $13.8M 2024-04-03 Glory Ventures, ZSVC, Changxing Financial Holdings 2020
Boyuan Biotechnology Boyuan Biotechnology offers a one-stop service platform for animal and plant functional gene research. Biotech Wuhan Series A $1.4M 2024-01-05 Addor Capital 101 to 250 2011
Changsha Morning Shine Changsha Morning Shine is a pharmaceutical company offering CDMO, chemical drug, and biotechnology services. Biotech Changshan Series A $14.1M 2023-12-14 $14.1M BioVenture, Jolmo Capital, Sunz Fund 2019
Hanhong Technology Hanhong Technology is a biomedicine firm focused on drug research, synthetic biology, and pharmaceutical intermediates. Biotech Xuhui Series A $13.9M 2023-12-11 WisdoMont Asset Management, Jinshuihu Fund 101 to 250 2003
Gachun Biotech Gachun Biotech runs an industrial platform producing active pharmaceutical ingredients and pharmaceutical intermediates. Biotech Chengdu Series A $14.1M 2023-11-23 $14.1M BioVenture, Si Chuan Venture Capital 11 to 50 2017
Bowang Pharmaceutical Bowang Pharmaceutical develops siRNA drugs on an RNAi drug research and development platform. Biotech Jiading Series A $41.0M 2023-11-01 GSR United Capital, Huagai Capital, SDIC Fund Management +2 51 to 100 2021

Table 1. Biotech startups that raised Series A in China: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 485.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 MoleculeMind MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. Artificial intelligence Haidian Series A $86.0M 2026-06-17 $114.6M Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital 51 to 100 2022
2 Allink Biotherapeutics Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. Biotech Shanghai Series A $47.0M 2025-12-16 $89.0M Legend Capital, Gaorong Capital, BioVenture +2 11 to 50 2023
3 Degron Therapeutics Degron Therapeutics discovers molecular glue degraders for cancer treatment. Biotech Shanghai Series A $40.0M 2026-05-14 $94.0M Baidu Ventures, BioVenture, New Alliance Capital +2 101 to 250 2021
4 Phil Rivers Technology Phil Rivers Technology provides AI solutions for pharmaceutical research and development. Artificial intelligence Beijing Series A $29.6M 2026-08-05 $57.3M Insight Capital 51 to 100 2015
5 Tianhu Technology Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. Artificial intelligence Minhang Series A $29.0M 2026-07-13 $54.2M Qiming Venture Partners, GSR United Capital, 3E Bioventures 11 to 50 2021
6 Artivila Therapeutics Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. Artificial intelligence Shenzhen Series A $14.7M 2026-06-23 $53.3M Highlight Capital, Med-Fine Capital, Hike Capital +2 11 to 50 2018
7 Prime Lifescience Prime Lifescience develops a big data platform for life sciences research and analysis. Biotech Hangzhou Series A $14.7M 2026-06-30 $44.5M Qiming Venture Partners, Qiji Investment, Ennovation Ventures 11 to 50 2021
8 SynMetaBio SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. Biotech Shanghai Series A $14.7M 2026-07-06 $16.1M MiraclePlus, Linear Capital, Danen Capital 11 to 50 2021
9 Shanmu SHANMU Shanmu develops micro medical robots using digital microfluidic chipsets and artificial intelligence algorithms. Artificial intelligence Shenzhen Series A $14.7M 2026-05-06 $16.0M QF Capital, Hofan Venture, Wanwu Capital +1 1 to 10 2020
10 Neurodome Neurodome manufactures non-invasive deep brain nerve modulation technology and products. Biotech Xian Shi Series A $14.5M 2026-03-12 $14.5M Shunwei Capital, Frees Fund, Oriza Holdings +2 11 to 50 2019

Table 2. Biotech startups that raised Series A in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 BioVenture Venture capital firm Suzhou, China 6 1% 2 Degron Therapeutics, Allink Biotherapeutics
2 Qiming Venture Partners Venture capital firm Shanghai, China 5 1% 3 Tianhu Technology, Prime Lifescience, PRCXI Biotechnology
3 CDH Investments Private equity firm Kowloon City, Hong Kong 4 1% 1 UniXell Biotechnology
4 Gaorong Capital Venture capital firm Wangjing, China 3 1% 2 BioGeometry, Allink Biotherapeutics
5 Legend Capital Venture capital firm Beijing, China 3 1% 2 Lingtai Krypton Biotechnology, Allink Biotherapeutics
6 Frees Fund Venture capital firm Beijing, China 3 1% 1 Neurodome
7 Shaanxi Investment Capital Venture capital firm Xian, China 3 1% 1 Neurodome
8 Hillhouse Investment Angel group Singapore 3 1% 2 UniXell Biotechnology, Dishi Medical
9 SZHTI Group Venture capital firm Shenzhen, China 3 1% 2 Newdel Biotech, JGene Biotechnology
10 Haitang Fund Venture capital firm Nankai, China 3 1% 1 Xingsai Bio
11 Taiyu Investment Venture capital firm Beijing, China 3 1%
12 Kaitai Capital Venture capital firm Hangzhou, China 3 1%
13 Insight Capital Venture capital firm Beijing, China 2 0% 1 Phil Rivers Technology
14 GSR United Capital Venture capital firm Beijing, China 2 0% 1 Tianhu Technology
15 3E Bioventures Venture capital firm Beijing, China 2 0% 1 Tianhu Technology

Table 3. Biotech startups that raised Series A in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 397 82% $6.2B
Software 32 7% $883.6M
Artificial intelligence 22 5% $837.1M
Hardware 11 2% $32.2M
Energy 4 1% $61.8M
Cybersecurity 4 1%
Commerce 2 0%
Education 1 0%

Table 4. Biotech startups that raised Series A in China by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series A 485 100% $14.0M

Table 5. Biotech startups that raised Series A in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Shanghai 76 16%
Hangzhou 37 8%
Beijing 35 7%
Shenzhen 34 7%
Suzhou 32 7%
Nanjing 26 5%
Haidian 20 4%
Guangzhou 14 3%
Chengdu 14 3%
Pudong 10 2%
Wuhan 10 2%
Changping 8 2%

Table 6. Biotech startups that raised Series A in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 2 2% $50.0M
October 2026 9 9% $91.2M
September 2026 1 1% $290.0M
August 2026 11 11% $153.5M
July 2026 12 12% $149.5M
June 2026 5 5% $158.7M
May 2026 11 11% $150.3M
April 2026 3 3% $52.6M
March 2026 5 5% $29.0M
February 2026 5 5% $21.7M
January 2026 17 17% $92.6M
December 2025 14 14% $196.3M
November 2025 8 8% $36.6M

Table 7. Biotech startups that raised Series A in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 81 17% $1.2B
2025 86 18% $841.8M
2024 66 14% $385.2M
2023 63 13% $746.6M
2022 43 9% $934.5M
2021 29 6% $486.4M

Table 8. Biotech startups that raised Series A in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 25 5%
2020 to 2022 163 34%
2015 to 2019 163 34%
2010 to 2014 72 15%
Before 2010 50 11%

Table 9. Biotech startups that raised Series A in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 30 8%
11 to 50 174 48%
51 to 100 84 23%
101 to 250 37 10%
251 to 500 21 6%
501 to 1,000 7 2%
1,001 to 5,000 8 2%
5,001 to 10,000 1 0%
10,001 or more 2 1%

Table 10. Biotech startups that raised Series A in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in China whose last round is Series A are on the list?
485, in the file dated 16 November 2026. 103 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 485 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series A in China: 485 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in China

Other sectors that raised Series A in China

Cite: FundingWatcher, 485 biotech companies in China whose most recent round is Series A, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-a/china-500a/